202 related articles for article (PubMed ID: 9305902)
1. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway.
Endo F; Kubo S; Awata H; Kiwaki K; Katoh H; Kanegae Y; Saito I; Miyazaki J; Yamamoto T; Jakobs C; Hattori S; Matsuda I
J Biol Chem; 1997 Sep; 272(39):24426-32. PubMed ID: 9305902
[TBL] [Abstract][Full Text] [Related]
2. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice.
Sun MS; Hattori S; Kubo S; Awata H; Matsuda I; Endo F
J Am Soc Nephrol; 2000 Feb; 11(2):291-300. PubMed ID: 10665936
[TBL] [Abstract][Full Text] [Related]
3. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.
Endo F; Sun MS
J Inherit Metab Dis; 2002 May; 25(3):227-34. PubMed ID: 12137232
[TBL] [Abstract][Full Text] [Related]
4. Animal models of tyrosinemia.
Nakamura K; Tanaka Y; Mitsubuchi H; Endo F
J Nutr; 2007 Jun; 137(6 Suppl 1):1556S-1560S; discussion 1573S-1575S. PubMed ID: 17513424
[TBL] [Abstract][Full Text] [Related]
5. Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1.
Kelsey G; Ruppert S; Beermann F; Grund C; Tanguay RM; Schütz G
Genes Dev; 1993 Dec; 7(12A):2285-97. PubMed ID: 8253377
[TBL] [Abstract][Full Text] [Related]
6. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors.
Kubo S; Sun M; Miyahara M; Umeyama K; Urakami K; Yamamoto T; Jakobs C; Matsuda I; Endo F
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9552-7. PubMed ID: 9689118
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
[TBL] [Abstract][Full Text] [Related]
9. Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus.
Klebig ML; Russell LB; Rinchik EM
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1363-7. PubMed ID: 1741389
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.
Dieter MZ; Freshwater SL; Miller ML; Shertzer HG; Dalton TP; Nebert DW
Free Radic Biol Med; 2003 Aug; 35(4):351-67. PubMed ID: 12899938
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
12. Animal models reveal pathophysiologies of tyrosinemias.
Endo F; Tanaka Y; Tomoeda K; Tanoue A; Tsujimoto G; Nakamura K
J Nutr; 2003 Jun; 133(6 Suppl 1):2063S-2067S. PubMed ID: 12771366
[TBL] [Abstract][Full Text] [Related]
13. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
14. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
Morrow G; Angileri F; Tanguay RM
Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
[TBL] [Abstract][Full Text] [Related]
15. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
St-Louis M; Tanguay RM
Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
[TBL] [Abstract][Full Text] [Related]
17. Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
Neuckermans J; Lequeue S; Claes P; Heymans A; Hughes JH; Colemonts-Vroninks H; Marcélis L; Casimir G; Goyens P; Martens GA; Gallagher JA; Vanhaecke T; Bou-Gharios G; De Kock J
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980965
[TBL] [Abstract][Full Text] [Related]
18. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
19. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
20. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.
Grompe M; al-Dhalimy M; Finegold M; Ou CN; Burlingame T; Kennaway NG; Soriano P
Genes Dev; 1993 Dec; 7(12A):2298-307. PubMed ID: 8253378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
